Karl Pfleger

Pfleger has publicly endorsed a clear rejuvenation framework: treating aging itself as pathology, repairing accumulated molecular damage, and pursuing divide-and-conquer interventions across multiple aging mechanisms. This is concrete and ambitious enough for a moderate-to-strong future_vision score, but the evidence lacks destination-level statements, timelines, explicit end-state goals, or repeated public vision quotes, limiting both score and confidence.

Scientific impact applies, but the provided evidence is very thin and contains no citation_metrics source, which the rubric says should be the primary signal. The only primary evidence is one co-authored 2015 Frontiers in Genetics paper about public desire for extended healthy life. That suggests some direct scientific/public-agenda contribution, but there is no evidence here of highly cited work, field-defining technical contributions, clinical trials, translational programs, or sustained scientific influence.

The evidence only shows Karl Pfleger as a coauthor on a longevity-related public-attitudes paper, with no disclosed investments, donations, funding amounts, or institution-building resources directed toward longevity.

No supplied evidence of personal capital deployment, philanthropy, fund allocation, or longevity institution-building activity.

Strategic_taste applies because the evidence concerns a longevity-field initiative, but the record is very thin. Founding AgingBiotech.info suggests a thesis-coherent focus on aging biotech information, and the cited paper indicates concern with correcting public understanding to avoid research misallocation. However, there is no evidence of early, contrarian, counterfactually important bets, investment/donation strategy, stage preference, risk appetite, or a clear strategic thesis.

The dimension applies because there is evidence of organization creation, but the record here is thin. The strongest field-creation signal is founding AgingBiotech.info, which suggests an effort to make the aging biotech space more legible. The cited paper also contributes to framing public demand for healthy life extension, but it is not direct evidence of creating a durable organization, program, protocol, community, or funding path. No independent or primary evidence here corroborates substantial achieved field-building impact beyond these limited signals.

The dimension applies, but the provided evidence contains almost no direct indicators of public risk-taking, personal downside, contrarian campaigning, sustained conviction under criticism, or self-experimentation. The single paper shows Pfleger publicly contributed to a pro-longevity framing around desire for longer healthy lives, but this is weak evidence of bravery or conviction under the rubric.

The dimension applies, but the provided evidence shows only modest second-order leverage. Pfleger founded AgingBiotech.info and co-authored a paper intended to inform public/resource allocation views about longevity research, but there is no concrete evidence here that he attracted major talent, capital, policy attention, founders, collaborators, public legitimacy, or follow-on projects at scale.